Focused On-demand Library for N(G),N(G)-dimethylarginine dimethylaminohydrolase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O95865

UPID:

DDAH2_HUMAN

Alternative names:

DDAHII; Dimethylargininase-2; Protein G6a; S-phase protein

Alternative UPACC:

O95865; A2BEZ7

Background:

N(G),N(G)-dimethylarginine dimethylaminohydrolase 2, also known as DDAHII, plays a crucial role in the regulation of nitric oxide (NO) production by hydrolyzing N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA). These substrates act as inhibitors of nitric oxide synthase (NOS), suggesting DDAHII's pivotal role in modulating NO levels.

Therapeutic significance:

Understanding the role of N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 could open doors to potential therapeutic strategies. Its critical function in regulating nitric oxide, a key molecule in cardiovascular health, positions it as a target for therapeutic intervention in related diseases.